Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Astex Pharmaceuticals Shares Skyrocketed

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Astex Pharmaceuticals (UNKNOWN: ASTX.DL  ) , a developer of small-molecule therapies focused on treating various types of cancer, soared as much as 26% after reporting positive top-line data for SGI-110 in a mid-stage trial for the treatment of acute myeloid leukemia, or AML.

So what: According to Astex's press release, 67 patients with AML -- 50 with refractory/relapsed AML, and 17 treatment-naive patients -- were treated in this study and had a minimum follow-up of three months. The primary endpoint of the study was overall remission rate, of which Astex reported eight remission among refractory/relapsed patients and nine among treatment-naive patients for an overall complete remission rate of 25%. Astex plans to release detailed results of its study in December at the American Society of Hematology's annual meeting.

Now what: Astex may be a small-cap biopharmaceutical company, but it has been cranking out fantastic results over the past year. Astex currently has seven ongoing clinical trials (including SGI-110) and an FDA-approved drug in Dacogen, as well as numerous clinical and preclinical partnerships with some of the pharmaceutical sectors' largest companies. With $133 million in cash and no debt, I'd say Astex certainly deserves a spot on your watchlist moving forward.

It's no secret that most biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 28, 2013, at 3:40 PM, Hope4GoodFuture wrote:

    Sean, do you know why Abingworth (one of the largest shareholders w/ a seat on the Board) sold all its shares over the last 2 quarters? Seems very strange.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2614197, ~/Articles/ArticleHandler.aspx, 9/30/2016 3:02:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,342.96 199.51 1.10%
S&P 500 2,172.41 21.28 0.99%
NASD 5,322.20 53.05 1.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ASTX.DL $0.00 Down +0.00 +0.00%
Astex Pharmaceutic… CAPS Rating: ***